A citation-based method for searching scientific literature

Akshitha Thatiparthi, Amylee Martin, Jeffrey Liu, Alexander Egeberg, Jashin J Wu. Am J Clin Dermatol 2021
Times Cited: 15







List of co-cited articles
33 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Psoriasis Pathogenesis and Treatment.
Adriana Rendon, Knut Schäkel. Int J Mol Sci 2019
375
20



Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors.
Keira A Fieldhouse, Samantha Ukaibe, Erika L Crowley, Reena Khanna, Ashley O'Toole, Melinda J Gooderham. Drugs Context 2020
23
13

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Craig L Leonardi, Alexa B Kimball, Kim A Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T Dooley, Kenneth B Gordon. Lancet 2008
13

IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis.
Andrew Johnston, Xianying Xing, Liza Wolterink, Drew H Barnes, ZhiQiang Yin, Laura Reingold, J Michelle Kahlenberg, Paul W Harms, Johann E Gudjonsson. J Allergy Clin Immunol 2017
150
13

Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
Xintong Li, Kathleen M Andersen, Hsien-Yen Chang, Jeffrey R Curtis, G Caleb Alexander. Ann Rheum Dis 2020
28
13

IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications.
Esther von Stebut, Wolf-Henning Boehncke, Kamran Ghoreschi, Tommaso Gori, Ziya Kaya, Diamant Thaci, Andreas Schäffler. Front Immunol 2020
60
13


Treatment of Psoriasis With Biologic Therapy Is Associated With Improvement of Coronary Artery Plaque Lipid-Rich Necrotic Core: Results From a Prospective, Observational Study.
Harry Choi, Domingo E Uceda, Amit K Dey, Khaled M Abdelrahman, Milena Aksentijevich, Justin A Rodante, Youssef A Elnabawi, Aarthi Reddy, Andrew Keel, Julie Erb-Alvarez,[...]. Circ Cardiovasc Imaging 2020
35
13

Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities.
Paolo Gisondi, Francesco Bellinato, Giampiero Girolomoni, Cristina Albanesi. Front Pharmacol 2020
33
13

Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study.
Youssef A Elnabawi, Amit K Dey, Aditya Goyal, Jacob W Groenendyk, Jonathan H Chung, Agastya D Belur, Justin Rodante, Charlotte L Harrington, Heather L Teague, Yvonne Baumer,[...]. Cardiovasc Res 2019
127
13

TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management.
Sara Jiayang Li, Lourdes M Perez-Chada, Joseph F Merola. J Psoriasis Psoriatic Arthritis 2019
27
13

Psoriasis and Co-morbidity.
Mina Amin, Erica B Lee, Tsen-Fang Tsai, Jashin J Wu. Acta Derm Venereol 2020
18
13

Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities.
Caleb Jeon, Mio Nakamura, Sahil Sekhon, Di Yan, Jashin J Wu, Wilson Liao, Tina Bhutani. JAAD Case Rep 2017
15
13

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
A Deodhar, P J Mease, I B McInnes, X Baraliakos, K Reich, A Blauvelt, C Leonardi, B Porter, A Das Gupta, A Widmer,[...]. Arthritis Res Ther 2019
130
13


Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt. Lancet 2019
121
13

Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
K Reich, R B Warren, L Iversen, L Puig, I Pau-Charles, A Igarashi, M Ohtsuki, M Falqués, M Harmut, S Rozzo,[...]. Br J Dermatol 2020
50
13

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
Atul Deodhar, Alice B Gottlieb, Wolf-Henning Boehncke, Bin Dong, Yuhua Wang, Yanli Zhuang, William Barchuk, Xie L Xu, Elizabeth C Hsia. Lancet 2018
101
13

Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
Kristian Reich, Christopher E M Griffiths, Kenneth B Gordon, Kim A Papp, Michael Song, Bruce Randazzo, Shu Li, Yaung-Kaung Shen, Chenglong Han, Alexa B Kimball,[...]. J Am Acad Dermatol 2020
36
13


Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study.
Hsien-Yi Chiu, Rosaline Chung-Yee Hui, Yu-Huei Huang, Ruey-Yun Huang, Kai-Lung Chen, Ya-Chu Tsai, Po-Ju Lai, Ting-Shun Wang, Tsen-Fang Tsai. Acta Derm Venereol 2018
34
13

Management of psoriatic patients in biologic treatment associated with infectious comorbidities.
Bernardini Nicoletta, Narcisi Alessandra, Skroza Nevena, Ersilia Tolino, Daniela Colapietra, Mastroianni Claudio, Potenza Concetta. Postepy Dermatol Alergol 2020
2
100

Treatment of severe psoriasis with ixekizumab in a liver transplant recipient with concomitant hepatitis B virus infection.
Viviana Lora, Dario Graceffa, Catia De Felice, Aldo Morrone, Claudio Bonifati. Dermatol Ther 2019
10
20

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update.
C H Smith, Z Z N Yiu, T Bale, A D Burden, L C Coates, W Edwards, E MacMahon, S K Mahil, A McGuire, R Murphy,[...]. Br J Dermatol 2020
62
13

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Kristian Reich, Kim A Papp, Andrew Blauvelt, Stephen K Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, Nicole Cichanowitz, Qing Li,[...]. Lancet 2017
276
13

Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic Arthritis.
Yinzhu Jin, Hemin Lee, Moa P Lee, Joan E Landon, Joseph F Merola, Rishi J Desai, Seoyoung C Kim. Arthritis Care Res (Hoboken) 2021
6
33

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
Alan Menter, Bruce E Strober, Daniel H Kaplan, Dario Kivelevitch, Elizabeth Farley Prater, Benjamin Stoff, April W Armstrong, Cody Connor, Kelly M Cordoro, Dawn M R Davis,[...]. J Am Acad Dermatol 2019
268
13


Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.
Xavier Mariette, Frauke Förger, Bincy Abraham, Ann D Flynn, Anna Moltó, René-Marc Flipo, Astrid van Tubergen, Laura Shaughnessy, Jeff Simpson, Marie Teil,[...]. Ann Rheum Dis 2018
173
13

Etanercept treatment for children and adolescents with plaque psoriasis.
Amy S Paller, Elaine C Siegfried, Richard G Langley, Alice B Gottlieb, David Pariser, Ian Landells, Adelaide A Hebert, Lawrence F Eichenfield, Vaishali Patel, Kara Creamer,[...]. N Engl J Med 2008
266
13

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.
Ian Landells, Colleen Marano, Ming-Chun Hsu, Shu Li, Yaowei Zhu, Lawrence F Eichenfield, Peter H Hoeger, Alan Menter, Amy S Paller, Alain Taieb,[...]. J Am Acad Dermatol 2015
124
13

Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature.
E Andreadou, E Kemanetzoglou, Ch Brokalaki, M E Evangelopoulos, C Kilidireas, A Rombos, E Stamboulis. Case Rep Neurol Med 2013
40
6

Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary.
Giulia Lavinia Fonti, Maria Sole Chimenti, Elisabetta Greco, Laura Boffa, Paola Conigliaro, Paola Triggianese, Roberto Perricone. Clin Exp Rheumatol 2021
2
50


Infliximab-Associated Chronic Inflammatory Central Nervous System Disease and Peroneal Nerve Injury in a Psoriatic Patient Refractory to Treatment: Case Report with 10-Year Follow-Up.
Sandra C Signore, Birka Brauns, Gunther Schütze, Christoph P Dohm, Mathias Bähr, Rotraut Mössner, Pawel Kermer. Case Rep Neurol 2018
3
33

Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors.
Andrew J Solomon, Rebecca I Spain, Michael C Kruer, Dennis Bourdette. Mult Scler 2011
66
6

A narrative review of psoriasis and multiple sclerosis: links and risks.
Annika S Silfvast-Kaiser, Katie B Homan, Bobbak Mansouri. Psoriasis (Auckl) 2019
11
9

A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions.
Martin Diebold, Simon Müller, Tobias Derfuss, Bernhard F Décard. Mult Scler Relat Disord 2019
9
11

Multiple sclerosis following anti-tumor necrosis factor-alpha therapy for psoriasis: first case in Italy?
Maddalena Napolitano, Nicola Balato, Fabio Ayala, Teresa Cirillo, Anna Balato. G Ital Dermatol Venereol 2018
2
50

Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature.
Satveer K Mahil, Thomasin C Andrews, Charlotte Brierley, Jonathan N Barker, Catherine H Smith. J Dermatolog Treat 2013
20
6


Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis.
Juan Escalas, Nicole Knöpfel, Ana Martin-Santiago, Carmen Calles. J Am Acad Dermatol 2014
5
20

Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab.
Teresa Ruiz-Jimeno, Alejandra Carvajal, Cristina Mata, Elena Aurrecoechea. J Rheumatol 2006
23
6

Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events.
Amy Kunchok, Allen J Aksamit, John M Davis, Orhun H Kantarci, B Mark Keegan, Sean J Pittock, Brian G Weinshenker, Andrew McKeon. JAMA Neurol 2020
37
6

Extensive and severe CNS demyelination associated with golimumab therapy.
Elisabeth Maillart, Caroline Papeix, Charles Mellerio, Anne Bertrand, Catherine Lubetzki, Céline Louapre. J Neurol 2016
7
14


Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy.
Alexander Winkelmann, Robert Patejdl, Sabine Wagner, Reiner Benecke, Uwe Klaus Zettl. J Neurol 2008
23
6

8
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.